Search

Your search keyword '"Azulay, Jean Philippe"' showing total 530 results
Start Over Author "Azulay, Jean Philippe"
530 results on '"Azulay, Jean Philippe"'

2. Imbalanced motivated behaviors according to motor sign asymmetry in drug-naïve Parkinson’s disease

Author

Béreau, Matthieu, Castrioto, Anna, Servant, Mathieu, Lhommée, Eugénie, Desmarets, Maxime, Bichon, Amélie, Pélissier, Pierre, Schmitt, Emmanuelle, Klinger, Hélène, Longato, Nadine, Phillipps, Clélie, Wirth, Thomas, Fraix, Valérie, Benatru, Isabelle, Durif, Franck, Azulay, Jean-Philippe, Moro, Elena, Broussolle, Emmanuel, Thobois, Stéphane, Tranchant, Christine, Krack, Paul, and Anheim, Mathieu

Published
2023
Full Text
View/download PDF

3. Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson’s Disease Motor Progression

Author

Jackson, Holly, Anzures-Cabrera, Judith, Taylor, Kirsten I, Pagano, Gennaro, Investigators, PASADENA, Group, Prasinezumab Study, Altendorf, Claudia, Anandan, Chareyna, Andrews, Giulia, Ansquer, Solène, Arrouasse, Raphaele, Aslam, Sana, Azulay, Jean-Philippe, Baker, Jeanette, Martinez, Ernest Balaguer, Barbu, Shadi, Bardram, Kara, Bega, Danny, Marco, Helena Bejr-Kasem, Benatru, Isabelle, Benchetrit, Eve, Bernhard, Felix, Besharat, Amir, Bette, Sagari, Bichon, Amelie, Billnitzer, Andrew, Blondeau, Sophie, Boraud, Thomas, Borngräber, Freiderike, Boyd, James, Brockmann, Kathrin, Brodsky, Matthew, Brown, Ethan, Bruecke, Christof, Calvas, Fabienne, Canelo, Monica, Carbone, Federico, Carroll, Claire, Fernandez, Laura Casado, Cassé-Perrot, Catherine, Castrioto, Anna, Catala, Helene, Chan, Justine, Cheriet, Samia, Ciabarra, Anthony, Classen, Joseph, Coleman, Juliana, Coleman, Robert, Compta, Yaroslau, Corbillé, Anne-Gaëlle, Corvol, Jean-Christophe, Cosgaya, Mariana, Dahodwala, Nabila, Damier, Philippe, David, Elodie, Davis, Thomas, Dean, Marissa, Debilly, Berengere, DeGiorgio, Janell, Deik, Andres, Delaby, Laure, Delfini, Marie-Helene, Derkinderen, Pascal, Derost, Philipp, de Toledo, Maria, Deuel, Lisa, Diaz-Hernandez, Ann Marie, Dietiker, Cameron, Dimenshteyn, Karina, Dotor, Julio, Durif, Franck, Ebentheuer, Jens, Eggert, Karla Maria, Madueño, Sara Eichau, Eickhoff, Claudia, Ellenbogen, Aaron, Ellmerer, Philipp, Vazquez, Ines Esparragosa, Eusebio, Alexandre, Ewert, Siobhan, Fang, John, Feigenbaum, Danielle, Fluchere, Frederique, Foubert-Samier, Alexandra, Fournier, Marie, Fradet, Anne, Fraix, Valerie, Frank, Samuel, Fries, Franca, Galitzky, Monique, Pérez, Marisol Gallardó, Moreno, Jose Manuel García, Gasca, Carmen, Gasser, Thomas, Gibbons, Joyce, Giordana, Caroline, Martinez, Alicia Gonzalez, Goodman, Ira, Gorospe, Arantza, and Goubeaud, Marie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Psychology, Biomedical Imaging, Parkinson's Disease, Brain Disorders, Clinical Research, Aging, Neurosciences, Neurodegenerative, Clinical Trials and Supportive Activities, Neurological, PASADENA Investigators, Prasinezumab Study Group, Dat-SPECT imaging, MDS-UPDRS, PASADENA, PPMI, Parkinson’s disease, disease stage, progression predictors, ridge regression, Cognitive Sciences, Biological psychology
Abstract

Currently, no treatments available for Parkinson's disease (PD) can slow PD progression. At the early stage of the disease, only a subset of individuals with PD progress quickly, while the majority have a slowly progressive form of the disease. In developing treatments that aim to slow PD progression, clinical trials aim to include individuals who are likely to progress faster, such that a treatment effect, if one exists, can be identified easier and earlier. The aim of the present study was to identify baseline predictors of clinical progression in early PD. We analyzed 12-month data acquired from the PASADENA trial Part 1 (NCT03100149, n = 76 participants who were allocated to the placebo arm and did not start symptomatic therapy) and the Parkinson's Progression Markers Initiative (PPMI) study (n = 139 demographically and clinically matched participants). By using ridge regression models including clinical characteristics, imaging, and non-imaging biomarkers, we found that Hoehn and Yahr stage and dopamine transporter single-photon emission computed tomography specific binding ratios (Dat-SPECT SBR) in putamen ipsilateral to the side of motor symptom onset predicted PD progression at the early stage of the disease. Further studies are needed to confirm the validity of these predictors to identify with high accuracy individuals with early PD with a faster progression phenotype.

Published
2021

4. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

Author

Pagano, Gennaro, Boess, Frank G, Taylor, Kirsten I, Ricci, Benedicte, Mollenhauer, Brit, Poewe, Werner, Boulay, Anne, Anzures-Cabrera, Judith, Vogt, Annamarie, Marchesi, Maddalena, Post, Anke, Nikolcheva, Tania, Kinney, Gene G, Zago, Wagner M, Ness, Daniel K, Svoboda, Hanno, Britschgi, Markus, Ostrowitzki, Susanne, Simuni, Tanya, Marek, Kenneth, Koller, Martin, Sevigny, Jeff, Doody, Rachelle, Fontoura, Paulo, Umbricht, Daniel, Bonni, Azad, Investigators, PASADENA, Group, Prasinezumab Study, Altendorf, Claudia, Anandan, Chareyna, Andrews, Giulia, Ansquer, Solène, Arrouasse, Raphaele, Aslam, Sana, Azulay, Jean-Philippe, Baker, Jeanette, Martinez, Ernest Balaguer, Barbu, Shadi, Bardram, Kara, Bega, Danny, Marco, Helena Bejr-Kasem, Benatru, Isabelle, Benchetrit, Eve, Bernhard, Felix, Besharat, Amir, Bette, Sagari, Bichon, Amelie, Billnitzer, Andrew, Blondeau, Sophie, Boraud, Thomas, Borngräber, Freiderike, Boyd, James, Brockmann, Kathrin, Brodsky, Matthew, Brown, Ethan, Bruecke, Christof, Calvas, Fabienne, Canelo, Monica, Carbone, Federico, Carroll, Claire, Fernandez, Laura Casado, Cassé-Perrot, Catherine, Castrioto, Anna, Catala, Helene, Chan, Justine, Cheriet, Samia, Ciabarra, Anthony, Classen, Joseph, Coleman, Juliana, Coleman, Robert, Compta, Yaroslau, Corbillé, Anne-Gaëlle, Corvol, Jean-Christophe, Cosgaya, Mariana, Dahodwala, Nabila, Damier, Philippe, David, Elodie, Davis, Thomas, Dean, Marissa, Debilly, Berengere, DeGiorgio, Janell, Deik, Andres, Delaby, Laure, Delfini, Marie-Helene, Derkinderen, Pascal, Derost, Philipp, de Toledo, Maria, Deuel, Lisa, Diaz-Hernandez, Ann Marie, Dietiker, Cameron, Dimenshteyn, Karina, Dotor, Julio, Durif, Franck, Ebentheuer, Jens, Eggert, Karla Maria, Madueño, Sara Eichau, Eickhoff, Claudia, Ellenbogen, Aaron, Ellmerer, Philipp, and Vazquez, Ines Esparragosa

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Neurodegenerative, Parkinson's Disease, Clinical Research, Neurosciences, Aging, Clinical Trials and Supportive Activities, Brain Disorders, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Neurological, PASADENA Investigators, Prasinezumab Study Group, MDS-UPDRS = Movement Disorder Society—Unified Parkinson's Disease Rating Scale, Parkinson's disease, Phase II clinical trial, alpha-synuclein, disease modification treatments, disease progression, monoclonal antibodies, prasinezumab, Psychology, Clinical sciences, Biological psychology
Abstract

Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. Objective: The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD. Methods: The PASADENA study is a multicenter, randomized, double-blind, placebo-controlled treatment study. Individuals with early PD, recruited across the US and Europe, received monthly intravenous doses of prasinezumab (1,500 or 4,500 mg) or placebo for a 52-week period (Part 1), followed by a 52-week extension (Part 2) in which all participants received active treatment. Key inclusion criteria were: aged 40-80 years; Hoehn & Yahr (H&Y) Stage I or II; time from diagnosis ≤2 years; having bradykinesia plus one other cardinal sign of PD (e.g., resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment naïve or on a stable monoamine oxidase B (MAO-B) inhibitor dose. Study design assumptions for sample size and study duration were built using a patient cohort from the Parkinson's Progression Marker Initiative (PPMI). In this report, baseline characteristics are compared between the treatment-naïve and MAO-B inhibitor-treated PASADENA cohorts and between the PASADENA and PPMI populations. Results: Of the 443 patients screened, 316 were enrolled into the PASADENA study between June 2017 and November 2018, with an average age of 59.9 years and 67.4% being male. Mean time from diagnosis at baseline was 10.11 months, with 75.3% in H&Y Stage II. Baseline motor and non-motor symptoms (assessed using Movement Disorder Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS]) were similar in severity between the MAO-B inhibitor-treated and treatment-naïve PASADENA cohorts (MDS-UPDRS sum of Parts I + II + III [standard deviation (SD)]; 30.21 [11.96], 32.10 [13.20], respectively). The overall PASADENA population (63.6% treatment naïve and 36.4% on MAO-B inhibitor) showed a similar severity in MDS-UPDRS scores (e.g., MDS-UPDRS sum of Parts I + II + III [SD]; 31.41 [12.78], 32.63 [13.04], respectively) to the PPMI cohort (all treatment naïve). Conclusions: The PASADENA study population is suitable to investigate the potential of prasinezumab to slow disease progression in individuals with early PD. Trial Registration: NCT03100149.

Published
2021

5. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations

Author

Brittain, Claire, McCarthy, Andrew, Irizarry, Michael C, McDermott, Dana, Biglan, Kevin, Höglinger, Günter U, Lorenzl, Stefan, del Ser, Teodoro, Boxer, Adam L, Group, The AL-108-231 Study, Williams, David, Lafontaine, Anne Louise, Marras, Connie, Jog, Mandar, Panisset, Michael, Lang, Anthony, Parker, Lesley, Stewart, Alistair J, Corvol, Jean-Christophe, Azulay, Jean-Philippe, Couratier, Philippe, Mollenhauer, Brit, Ludolph, Albert, Benecke, Reiner, Hoglinger, Gunter, Lipp, Axel, Reichmann, Heinz, Woitalla, Dirk, Chan, Dennis, Zermansky, Adam, Burn, David, Lees, Andrew, Gozes, Illana, Boxer, Adam, Miller, Bruce L, Lobach, Iryna V, Roberson, Erik, Honig, Lawrence, Zamrini, Edward, Pahwa, Rajesh, Bordelon, Yvette, Driver-Dunkley, Erika, Lessig, Stephanie, Lew, Mark, Womack, Kyle, Boeve, Brad, Ferrara, Joseph, Hillis, Argyle, Kaufer, Daniel, Kumar, Rajeev, Xie, Tao, Gunzler, Steven, Zesiewicz, Theresa, Dayalu, Praveen, Golbe, Lawrence, Grossman, Murray, Jankovic, Joseph, McGinnis, Scott, Santiago, Anthony, Tuite, Paul, Isaacson, Stuart, Leegwater-Kim, Julie, Litvan, Irene, Knopman, David S, Schneider, Lon S, Doody, Rachelle S, Golbe, Lawrence I, Roberson, Erik D, Koestler, Mary, Jack, Clifford R, Van Deerlin, Viviana, Randolph, Christopher, Whitaker, Steve, Hirman, Joe, Gold, Michael, Morimoto, Bruce H, investigators, The PROPSPERA, G, Georg Nuebling, Hensler, Mira, Paul, Sabine, Zwergal, Andreas, 4RNTI-1authors, Heuer, Hilary W, Tartaglia, Maria C, McGinnis, Scott M, Dickerson, Bradford C, Kornak, John, Schuff, Norbert, Rabinovici, Gil D, Rosen, Howard J, Investigators, Tau Restoration on PSP, Gómez, JC, Tijero, B, Berganzo, K, de Yebenes, J Garc'ıa, Sendón, JL Lopez, and Garcia, G

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Brain Disorders, Frontotemporal Dementia (FTD), Clinical Research, Aging, Alzheimer's Disease Related Dementias (ADRD), Health Disparities, Clinical Trials and Supportive Activities, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Acquired Cognitive Impairment, Neurodegenerative, Rare Diseases, Dementia, 4.2 Evaluation of markers and technologies, Neurological, Aged, Aged, 80 and over, Basal Ganglia Diseases, Data Visualization, Disease Progression, Female, Humans, Male, Middle Aged, Models, Neurological, Neurodegenerative Diseases, Prognosis, Severity of Illness Index, Supranuclear Palsy, Progressive, Syndrome, Corticobasal syndrome, Progressive supranuclear palsy, PSP rating scale, Interactive visualizations, Predictive models, AL-108-231 Study Group, PROPSPERA investigators, 4RNTI-1authors, Tau Restoration on PSP (TAUROS) Investigators, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences, Biological psychology
Abstract

BackgroundProgressive supranuclear palsy (PSP) -Richardson's Syndrome and Corticobasal Syndrome (CBS) are the two classic clinical syndromes associated with underlying four repeat (4R) tau pathology. The PSP Rating Scale is a commonly used assessment in PSP clinical trials; there is an increasing interest in designing combined 4R tauopathy clinical trials involving both CBS and PSP.ObjectivesTo determine contributions of each domain of the PSP Rating Scale to overall severity and characterize the probable sequence of clinical progression of PSP as compared to CBS.MethodsMulticenter clinical trial and natural history study data were analyzed from 545 patients with PSP and 49 with CBS. Proportional odds models were applied to model normalized cross-sectional PSP Rating Scale, estimating the probability that a patient would experience impairment in each domain using the PSP Rating Scale total score as the index of overall disease severity.ResultsThe earliest symptom domain to demonstrate impairment in PSP patients was most likely to be Ocular Motor, followed jointly by Gait/Midline and Daily Activities, then Limb Motor and Mentation, and finally Bulbar. For CBS, Limb Motor manifested first and ocular showed less probability of impairment throughout the disease spectrum. An online tool to visualize predicted disease progression was developed to predict relative disability on each subscale per overall disease severity.ConclusionThe PSP Rating Scale captures disease severity in both PSP and CBS. Modelling how domains change in relation to one other at varying disease severities may facilitate detection of therapeutic effects in future clinical trials.

Published
2019

6. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies

Author

Azulay, Jean-Philippe, Balaguer, Ernest, Bhatia, Perminder, Bodis-Wollner, Ivan, Brownstone, Paul, Boulloche, Nicolas, Calegan, Gerald J., II, Castelnovo, Giovanni, Chou, Kelvin L., Corvol, Jean-Christophe, Danisi, Fabio, Defebvre, Luc, Desojo, Lydia Vela, Durif, Franck, Ehret, Reinhard, Evans, Bradley K., Forchetti, Concetta, Friedman, Joseph H., Fogel, Wolfgang, Garniga, Matilde Calopa, Gil, Ramon A., Ginsberg, Paul L., Glasberg, Mark R., Griffith, Alida, Groves, Jeffrey W., Gudesblatt, Mark, Hermanowicz, Neal, Herrera, Maria A., Houeto, Jean-Luc, Hutchman, Robert M., Isaacson, Stuart H., Jagadeesan, Singar, Jog, Mandar, Keegan, Andrew, Klostermann, Fabian, Krystkowiak, Pierre, Kulisevsky Bojarsky, Jaime, Kumar, Rajeev, Lacey, Dennis, Lasker, Bruce, LaVaccare, John, Lavallee, Michelle M., Piudo, Maria Rosario Luquin, Mahler, Andreas, Domenech, Maria José Martí, Martinez Castrillo, Juan Carlos, Mate, Laszlo J., Mendis, Tilak, Metman, Leonard Verhagen, Muhlack, Siegfried Martin, Müller, Thomas, Park, Ariane, Patton, James, Peckham, Elizabeth, Grandas Pérez, Francisco, Rabin, Marcie, Rascol, Olivier, Reifschneider, Gerd, Remy, Philippe, Rivera, Pablo Mir, Schwarz, Johannes, Roullet-Solignac, Isabelle, Salazar, Gabriel, Sergay, Stephen M., Sherman, Scott, Shubin, Richard, Spikol, Lorraine, Steigerwald, Frank, Tönges, Lars, Truong, Daniel D., Ugarte, Antonio, Vivancos Matellano, Francisco, Witte, Arnold, Zesiewicz, Theresa, Zauber, Sarah Elizabeth, deVries, Tina, Jaros, Mark, Quartel, Adrian, and Jacobs, David

Published
2022
Full Text
View/download PDF

7. Electrophysiological features of the peripheral neuropathy in patients with pathologic biallelic RFC1 repeat expansions.

Author

Calezis, Claudia, Bonello‐Palot, Nathalie, Verschueren, Annie, Azulay, Jean‐Philippe, Fortanier, Etienne, Grapperon, Aude‐Marie, Kouton, Ludivine, Gallard, Julien, Salort‐Campana, Emmanuelle, Attarian, Shahram, and Delmont, Emilien

Abstract

Introduction/Aims: Cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS) is caused by RFC1 expansions. Sensory neuronopathy, polyneuropathy, and involvement of motor, autonomic, and cranial nerves have all been described with RFC1 expansions. We aimed to describe the electrodiagnostic features of patients with RFC1 expansions through multimodal electrophysiological investigations. Methods: Thirty‐five patients, with a median age of 70 years, and pathologic biallelic repeat expansions in the RFC1 gene, were tested for motor and sensory nerve conduction, flexor carpi radialis (FCR) and soleus H‐reflexes, blink reflex, electrochemical skin conductance, sympathetic skin response (SSR), and heart rate variability with deep breathing (HRV). Results: Only 16 patients (46%) exhibited the full clinical CANVAS spectrum. Distal motor amplitudes were normal in 30 patients and reduced in the legs of five patients. Distal sensory amplitudes were bilaterally reduced in a non‐length dependent manner in 30 patients. Conduction velocities were normal. Soleus H‐reflexes were abnormal in 19/20 patients of whom seven had preserved Achilles reflexes. FCR H‐reflexes were absent or decreased in amplitude in 13/14 patients. Blink reflex was abnormal in 4/19 patients: R1 latencies for two patients and R2 latencies for two others. Fourteen out of 31 patients (45%) had abnormal results in at least one autonomic nervous system test, either for ESC (12/31), SSR (5/14), or HRV (6/19). Discussion: Less than half of the patients with RFC1 expansions exhibited the full clinical CANVAS spectrum, but nearly all exhibited typical sensory neuronopathy and abnormal H‐reflexes. Involvement of small nerve fibers and brainstem neurons was less common. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP

Author

Rojas, Julio C, Bang, Jee, Lobach, Iryna V, Tsai, Richard M, Rabinovici, Gil D, Miller, Bruce L, Boxer, Adam L, Williams, David, Lafontaine, Anne Louise, Marras, Connie, Jog, Mandar, Panisset, Michael, Lang, Anthony, Parker, Lesley, Stewart, Alistair J, Corvol, Jean-Christophe, Azulay, Jean-Philippe, Couratier, Philippe, Mollenhauer, Brit, Lorenzl, Stefan, Ludolph, Albert, Benecke, Reiner, Hoglinger, Gunter, Lipp, Axel, Reichmann, Heinz, Woitalla, Dirk, Chan, Dennis, Zermansky, Adam, Burn, David, Lees, Andrew, Gozes, Illana, Boxer, Adam, Roberson, Erik, Honig, Lawrence, Zamrini, Edward, Pahwa, Rajesh, Bordelon, Yvette, Driver-Dunkley, Erika, Lessig, Stephanie, Lew, Mark, Womack, Kyle, Boeve, Brad, Ferrara, Joseph, Hillis, Argyle, Kaufer, Daniel, Kumar, Rajeev, Xie, Tao, Gunzler, Steven, Zesiewicz, Theresa, Dayalu, Praveen, Golbe, Lawrence, Grossman, Murray, Jankovic, Joseph, McGinnis, Scott, Santiago, Anthony, Tuite, Paul, Isaacson, Stuart, Leegwater-Kim, Julie, Litvan, Irene, Knopman, David S, Schneider, Lon S, Doody, Rachelle S, Koestler, Mary, Jack, Clifford R, Van Deerlin, Viviana, Randolph, Christopher, Whitaker, Steve, Hirman, Joe, Gold, Michael, and Morimoto, Bruce H

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Brain Disorders, Aging, Alzheimer's Disease, Neurodegenerative, Clinical Research, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Acquired Cognitive Impairment, Dementia, Neurological, Aged, Amyloid beta-Peptides, Biomarkers, Brain, Central Nervous System Agents, Disease Progression, Double-Blind Method, Female, Humans, Longitudinal Studies, Male, Neurofilament Proteins, Oligopeptides, Peptide Fragments, Phosphorylation, Prognosis, Severity of Illness Index, Supranuclear Palsy, Progressive, tau Proteins, AL-108-231 Investigators, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectiveTo determine the ability of CSF biomarkers to predict disease progression in progressive supranuclear palsy (PSP).MethodsWe compared the ability of baseline CSF β-amyloid1-42, tau, phosphorylated tau 181 (p-tau), and neurofilament light chain (NfL) concentrations, measured by INNO-BIA AlzBio3 or ELISA, to predict 52-week changes in clinical (PSP Rating Scale [PSPRS] and Schwab and England Activities of Daily Living [SEADL]), neuropsychological, and regional brain volumes on MRI using linear mixed effects models controlled for age, sex, and baseline disease severity, and Fisher F density curves to compare effect sizes in 50 patients with PSP. Similar analyses were done using plasma NfL measured by single molecule arrays in 141 patients.ResultsHigher CSF NfL concentration predicted more rapid decline (biomarker × time interaction) over 52 weeks in PSPRS (p = 0.004, false discovery rate-corrected) and SEADL (p = 0.008), whereas lower baseline CSF p-tau predicted faster decline on PSPRS (p = 0.004). Higher CSF tau concentrations predicted faster decline by SEADL (p = 0.004). The CSF NfL/p-tau ratio was superior for predicting change in PSPRS, compared to p-tau (p = 0.003) or NfL (p = 0.001) alone. Higher NfL concentrations in CSF or blood were associated with greater superior cerebellar peduncle atrophy (fixed effect, p ≤ 0.029 and 0.008, respectively).ConclusionsBoth CSF p-tau and NfL correlate with disease severity and rate of disease progression in PSP. The inverse correlation of p-tau with disease severity suggests a potentially different mechanism of tau pathology in PSP as compared to Alzheimer disease.

Published
2018

10. Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)

Author

Oertel, Wolfgang, Eggert, Karla, Pahwa, Rajesh, Tanner, Caroline M, Hauser, Robert A, Trenkwalder, Claudia, Ehret, Reinhard, Azulay, Jean Philippe, Isaacson, Stuart, Felt, Larissa, and Stempien, Mary Jean

Subjects
Brain Disorders, Clinical Research, Parkinson's Disease, Neurodegenerative, Clinical Trials and Supportive Activities, Neurosciences, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Amantadine, Antiparkinson Agents, Delayed-Action Preparations, Double-Blind Method, Dyskinesia, Drug-Induced, Female, Humans, Levodopa, Male, Middle Aged, Parkinson Disease, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome, Parkinson's disease, amantadine, Unified Dyskinesia Rating Scale, levodopa-induced dyskinesia, randomized controlled trial, Clinical Sciences, Human Movement and Sports Sciences, Neurology & Neurosurgery
Abstract

BackgroundThe treatment of levodopa-induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy.ObjectiveThe purpose of this study was to investigate the efficacy and safety of 274 mg ADS-5102 (amantadine) extended-release capsules (equivalent to 340-mg amantadine HCl) for levodopa-induced dyskinesia in a randomized controlled trial.MethodsPD patients with ≥1 hour of troublesome dyskinesia and at least mild functional impact were randomized to placebo or ADS-5102 once daily at bedtime for 13 weeks. The primary efficacy analysis was based on change from baseline to week 12 on the Unified Dyskinesia Rating Scale total score in the modified intent-to-treat population. OFF time was a key secondary measure.ResultsAt week 12, least-squares mean change in the Unified Dyskinesia Rating Scale was -20.7 (standard error 2.2) for ADS-5102 (n = 37) and -6.3 (standard error 2.1) for placebo (n = 38; treatment difference -14.4, 95% confidence interval -20.4 to -8.3, P < .0001), indicating improvement in levodopa-induced dyskinesia. OFF time decreased 0.5 hours (standard error 0.3) for ADS-5102 from a baseline mean of 2.6 hours and increased 0.6 hours (standard error 0.3) for placebo from a baseline mean of 2.0 hours (treatment difference -1.1 hours, 95% confidence interval -2.0 to -0.2, P = .0199). The most common adverse events (ADS-5102 versus placebo) included dry mouth (13.5% versus 2.6%), nausea (13.5% versus 2.6%), decreased appetite (10.8% versus 0%), insomnia (10.8% versus 0%), orthostatic hypotension (10.8% versus 0%), constipation (8.1% versus 0%), falls (8.1% versus 5.3%), and visual hallucinations (8.1% versus 5.3%). Adverse events led to treatment discontinuation in 19% versus 8%, respectively.ConclusionADS-5102 274 mg is an oral pharmacotherapy demonstrating a significant decrease in levodopa-induced dyskinesia and improving OFF time. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Published
2017

12. Increasing involvement of CAPN1 variants in spastic ataxias and phenotype-genotype correlations

Author

Méreaux, Jean-Loup, Firanescu, Cristina, Coarelli, Giulia, Kvarnung, Malin, Rodrigues, Rita, Pegoraro, Elena, Tazir, Meriem, Taithe, Frédéric, Valter, Rémi, Huin, Vincent, Lidström, Kristina, Banneau, Guillaume, Morais, Sara, Parodi, Livia, Coutelier, Marie, Papin, Mélanie, Svenningsson, Per, Azulay, Jean-Philippe, Alonso, Isabel, Nilsson, Daniel, Brice, Alexis, Le Guern, Eric, Press, Rayomand, Vazza, Giovanni, Loureiro, José Leal, Goizet, Cyril, Durr, Alexandra, Paucar, Martin, and Stevanin, Giovanni

Published
2021
Full Text
View/download PDF

13. Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.

Author

Quattrone, Andrea, Franzmeier, Nicolai, Huppertz, Hans‐Jürgen, Klietz, Martin, Roemer, Sebastian N., Williams, David, Lafontaine, Anne Louise, Marras, Connie, Jog, Mandar, Panisset, Michael, Lang, Anthony, Parker, Lesley, Stewart, Alistair J., Corvol, Jean‐Christophe, Azulay, Jean‐Philippe, Couratier, Philippe, Mollenhauer, Brit, Lorenzl, Stefan, Ludolph, Albert, and Benecke, Reiner

Abstract

Background: Several magnetic resonance imaging (MRI) measures have been suggested as progression biomarkers in progressive supranuclear palsy (PSP), and some PSP staging systems have been recently proposed. Objective: Comparing structural MRI measures and staging systems in tracking atrophy progression in PSP and estimating the sample size to use them as endpoints in clinical trials. Methods: Progressive supranuclear palsy‐Richardson's syndrome (PSP‐RS) patients with one‐year‐follow‐up longitudinal brain MRI were selected from the placebo arms of international trials (NCT03068468, NCT01110720, NCT01049399) and the DescribePSP cohort. The discovery cohort included patients from the NCT03068468 trial; the validation cohort included patients from other sources. Multisite age‐matched healthy controls (HC) were included for comparison. Several MRI measures were compared: automated atlas‐based volumetry (44 regions), automated planimetric measures of brainstem regions, and four previously described staging systems, applied to volumetric data. Results: Of 508 participants, 226 PSP patients including discovery (n = 121) and validation (n = 105) cohorts, and 251 HC were included. In PSP patients, the annualized percentage change of brainstem and midbrain volume, and a combined index including midbrain, frontal lobe, and third ventricle volume change, were the progression biomarkers with the highest effect size in both cohorts (discovery: >1.6; validation cohort: >1.3). These measures required the lowest sample sizes (n < 100) to detect 30% atrophy progression, compared with other volumetric/planimetric measures and staging systems. Conclusions: This evidence may inform the selection of imaging endpoints to assess the treatment efficacy in reducing brain atrophy rate in PSP clinical trials, with automated atlas‐based volumetry requiring smaller sample size than staging systems and planimetry to observe significant treatment effects. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Molecular Imaging in CANVAS: A Contribution for Differential Diagnosis?

Author

Horowitz, Tatiana, Guedj, Eric, Eusebio, Alexandre, Fluchère, Frédérique, Azulay, Jean‐Philippe, Delmont, Emilien, and Grimaldi, Stephan

Subjects
MULTIPLE system atrophy, CEREBELLUM degeneration, SINGLE-photon emission computed tomography, POSITRON emission tomography, DIFFERENTIAL diagnosis
Abstract

Background: Phenotypes of CANVAS are increasingly diversified, including bradykinesia and dysautonomia, so that its primary differential diagnoses are multiple system atrophy‐cerebellar type (MSA‐c), and spinocerebellar ataxia type 3 (SCA3). This case series aims to highlight key molecular imaging findings in CANVAS. Cases: We report a case series of six patients with CANVAS who underwent nuclear medicine examinations in our center and 13 patients from the literature. These include 18F‐FDG brain positron emission tomography (PET), single photon emission computed tomography (SPECT) of dopamine transporter (DaT) activity, and 123I‐MIBG cardiac scintigraphy of noradrenergic transmission. Conclusions: In CANVAS, 18F‐FDG brain PET mainly shows cerebellar hypometabolism, with preserved brainstem and striatum metabolism, contrasting with SCA3 and MSA‐c. Dopaminergic denervation on scintigraphy seems to be associated with clinical parkinsonism, ranging from normal to severely impaired DaT SPECT. Additionally, 123I‐MIBG cardiac scintigraphy might show denervation in CANVAS, similar to SCA3, but not in most MSA‐c patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Progression of brain atrophy in PSP and CBS over 6 months and 1 year

Author

Dutt, Shubir, Binney, Richard J, Heuer, Hilary W, Luong, Phi, Attygalle, Suneth, Bhatt, Priyanka, Marx, Gabe A, Elofson, Jonathan, Tartaglia, Maria C, Litvan, Irene, McGinnis, Scott M, Dickerson, Bradford C, Kornak, John, Waltzman, Dana, Voltarelli, Lisa, Schuff, Norbert, Rabinovici, Gil D, Kramer, Joel H, Jack, Clifford R, Miller, Bruce L, Rosen, Howard J, Boxer, Adam L, Williams, David, Lafontaine, Anne Louise, Marras, Connie, Jog, Mandar, Panisset, Michael, Lang, Anthony, Parker, Lesley, Stewart, Alistair J, Corvol, Jean-Christophe, Azulay, Jean-Philippe, Couratier, Philippe, Mollenhauer, Brit, Lorenzl, Stefan, Ludolph, Albert, Benecke, Reiner, Hoglinger, Gunter, Lipp, Axel, Reichmann, Heinz, Woitalla, Dirk, Chan, Dennis, Zermansky, Adam, Burn, David, Lees, Andrew, Gozes, Illana, Boxer, Adam, Lobach, Iryna V, Roberson, Erik, Honig, Lawrence, Zamrini, Edward, Pahwa, Rajesh, Bordelon, Yvette, Driver-Dunkley, Erika, Lessig, Stephanie, Lew, Mark, Womack, Kyle, Boeve, Brad, Ferrara, Joseph, Hillis, Argyle, Kaufer, Daniel, Kumar, Rajeev, Xie, Tao, Gunzler, Steven, Zesiewicz, Theresa, Dayalu, Praveen, Golbe, Lawrence, Grossman, Murray, Jankovic, Joseph, McGinnis, Scott, Santiago, Anthony, Tuite, Paul, Isaacson, Stuart, Leegwater-Kim, Julie, Knopman, David S, Schneider, Lon S, Doody, Rachelle S, Koestler, Mary, Van Deerlin, Viviana, Randolph, Christopher, Whitaker, Steve, Hirman, Joe, Gold, Michael, Morimoto, and , Bruce H

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Biomedical Imaging, Aging, Rare Diseases, Alzheimer's Disease, Clinical Research, Neurosciences, Brain Disorders, Acquired Cognitive Impairment, Neurodegenerative, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Dementia, 2.1 Biological and endogenous factors, Aetiology, Neurological, Aged, Atrophy, Basal Ganglia, Cerebral Cortex, Disease Progression, Female, Follow-Up Studies, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Middle Aged, Statistics, Nonparametric, Supranuclear Palsy, Progressive, AL-108-231 investigators, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectiveTo examine the utility and reliability of volumetric MRI in measuring disease progression in the 4 repeat tauopathies, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), to support clinical development of new tau-directed therapeutic agents.MethodsSix- and 12-month changes in regional MRI volumes and PSP Rating Scale scores were examined in 55 patients with PSP and 33 patients with CBS (78% amyloid PET negative) compared to 30 normal controls from a multicenter natural history study. Longitudinal voxel-based morphometric analyses identified patterns of volume loss, and region-of-interest analyses examined rates of volume loss in brainstem (midbrain, pons, superior cerebellar peduncle), cortical, and subcortical regions based on previously validated atlases. Results were compared to those in a replication cohort of 226 patients with PSP with MRI data from the AL-108-231 clinical trial.ResultsPatients with CBS exhibited greater baseline atrophy and greater longitudinal atrophy rates in cortical and basal ganglia regions than patients with PSP; however, midbrain and pontine atrophy rates were similar. Voxel-wise analyses showed distinct patterns of regional longitudinal atrophy in each group as compared to normal controls. The midbrain/pons volumetric ratio differed between diagnoses but remained stable over time. In both patient groups, brainstem atrophy rates were correlated with disease progression measured using the PSP Rating Scale.ConclusionsVolume loss is quantifiable over a period of 6 months in CBS and PSP. Future clinical trials may be able to combine CBS and PSP to measure therapeutic effects.

Published
2016

20. Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial

Author

Corvol, Jean-Christophe, Durif, Franck, Meissner, Wassilios G., Azulay, Jean-Philippe, Haddad, Raphaël, Guimarães-Costa, Raquel, Mariani, Louise-Laure, Cormier-Dequaire, Florence, Thalamas, Claire, Galitzky, Monique, Boraud, Thomas, Debilly, Bérengère, Eusebio, Alexandre, Houot, Marion, Dellapina, Estelle, Chaigneau, Véronique, Salis, Alexandrine, Lacomblez, Lucette, Benel, Laurent, and Rascol, Olivier

Published
2019
Full Text
View/download PDF

21. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations

Author

Williams, David, Lafontaine, Anne Louise, Marras, Connie, Jog, Mandar, Panisset, Michael, Lang, Anthony, Parker, Lesley, Stewart, Alistair J., Corvol, Jean-Christophe, Azulay, Jean-Philippe, Couratier, Philippe, Mollenhauer, Brit, Lorenzl, Stefan, Ludolph, Albert, Benecke, Reiner, Hoglinger, Gunter, Lipp, Axel, Reichmann, Heinz, Woitalla, Dirk, Chan, Dennis, Zermansky, Adam, Burn, David, Lees, Andrew, Gozes, Illana, Boxer, Adam, Miller, Bruce L., Lobach, Iryna V., Roberson, Erik, Honig, Lawrence, Zamrini, Edward, Pahwa, Rajesh, Bordelon, Yvette, Driver-Dunkley, Erika, Lessig, Stephanie, Lew, Mark, Womack, Kyle, Boeve, Brad, Ferrara, Joseph, Hillis, Argyle, Kaufer, Daniel, Kumar, Rajeev, Xie, Tao, Gunzler, Steven, Zesiewicz, Theresa, Dayalu, Praveen, Golbe, Lawrence, Grossman, Murray, Jankovic, Joseph, McGinnis, Scott, Santiago, Anthony, Tuite, Paul, Isaacson, Stuart, Leegwater-Kim, Julie, Litvan, Irene, Knopman, David S., Schneider, Lon S., Doody, Rachelle S., Golbe, Lawrence I., Roberson, Erik D., Koestler, Mary, Jack, Clifford R., Jr., Van Deerlin, Viviana, Randolph, Christopher, Whitaker, Steve, Hirman, Joe, Gold, Michael, Morimoto, Bruce H., Nuebling G, Georg, Hensler, Mira, Paul, Sabine, Zwergal, Andreas, Heuer, Hilary W., Tartaglia, Maria C., McGinnis, Scott M., Dickerson, Bradford C., Kornak, John, Schuff, Norbert, Rabinovici, Gil D., Rosen, Howard J., Boxer, Adam L., Gómez, J.C., Tijero, B., Berganzo, K., Garc'ıa de Yebenes, J., Lopez Sendón, J.L., Garcia, G., Tolosa, E., Buongiorno, M.T., Bargalló, N., Burguera, J.A., Martinez, I., Ruiz-Mart'ınez, J., Narrativel, I., Vivancos, F., Ybot, I., Aguilar, M., Quilez, P., Boada, M., Lafuente, A., Hernandez, I., López-Lozano, J.J., Mata, M., Kupsch, A., Lipp, A., Ebersbach, G., Schmidt, T., Hahn, K., Höglinger, G., Höllerhage, M., Oertel, W.H., Respondek, G., Stamelou, M., Reichmann, H., Wolz, M., Schneider, C., Klingelhöfer, L., Berg, D., Maetzler, W., Srulijes, K.K., Ludolph, A., Kassubek, J., Steiger, M., Tyler, K., Burn, D.J., Morris, L., Lees, A., Ling, H., Hauser, R., McClain, T., Truong, D., Jenkins, S., Litvan, I., Houghton, D., Ferrara, J., Bordelon, Y., Gratiano, A., Golbe, L., Mark, M., Uitti, R., Ven Gerpen, J., Brittain, Claire, McCarthy, Andrew, Irizarry, Michael C., McDermott, Dana, Biglan, Kevin, Höglinger, Günter U., and del Ser, Teodoro

Published
2019
Full Text
View/download PDF

25. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial

Author

Negovanska, Velina, Welter, Marie-Laure, Corvol, Jean-Christophe, Agid, Yves, Navarro, Soledad, Meier, Niklaus, Hartmann, Andreas, Hesekamp, Helke, Cornu, Philippe, Möller, Bettina, Nebel, Adelheid, Raethjen, Jan, Knudsen, Karina, Volkmann, Jens, Falk, Daniela, Paschen, Steffen, Meister, Ingo, Kuhn, Jens, Donner, Kerstin, Kessler, Josef, Barbe, Michael, Fink, Gereon, Maarouf, Mohammad, Kühn, Andrea, Müller, Bianca, Faust, Katharina, Gruber, Doreen, Schneider, Gerd-H., Seigneuret, Eric, Pollak, Pierre, Fraix, Valerie, Kistner, Andrea, Rascol, Olivier, Arbus, Christophe, Danet, Lola, Chaynes, Patrick, Groiss, Stefan J., Hartmann, Christian, Südmeyer, Martin, Partowinia-Peters, Mahnaz, Vesper, Jan, Ledily, Severine, Damier, Philippe, Raoul, Sylvie, Trenkwalder, Claudia, Richter-Dreske, Wenke, Wächter, Tobias, Weiss, Daniel, Eusebio, Alexandro, Azulay, Jean Philippe, Polo, Gustavo, Pinto, Serge, Levin, Johannes, Dornier, Stephanie, Pene, Fredy, Hourton, Delphine, Quintin, Mathieu, Hoffart-Jourdain, Cecile, Brocvielle, Helene, Balthasar, Kerstin, Stein, Meryem, Harnisch, Susanne, Reuss, Alexander, Aminossadati, Behnaz, Nasemann, Christian, Oertel, Wolfgang, Bataille, Benoit, Hellwig, Dieter, Gharabaghi, Alireza, Amtage, Florian, Mertens, Patrick, Kloss, Manja, Post, Bart, Speelman, Hans, Lhommée, Eugénie, Wojtecki, Lars, Czernecki, Virginie, Witt, Karsten, Maier, Franziska, Tonder, Lisa, Timmermann, Lars, Hälbig, Thomas D, Pineau, Fanny, Durif, Franck, Witjas, Tatiana, Pinsker, Marcus, Mehdorn, Maximilian, Sixel-Döring, Friederike, Kupsch, Andreas, Krüger, Rejko, Elben, Saskia, Chabardès, Stephan, Thobois, Stéphane, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Regis, Jean-Marie, Maltête, David, Sauvaget, Anne, Rau, Jörn, Schnitzler, Alfons, Schüpbach, Michael, Schade-Brittinger, Carmen, Deuschl, Gunther, Houeto, Jean-Luc, and Krack, Paul

Published
2018
Full Text
View/download PDF

28. Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson's disease.

Author

Béreau, Matthieu, Kibleur, Astrid, Servant, Mathieu, Clément, Gautier, Dujardin, Kathy, Rolland, Anne-Sophie, Wirth, Thomas, Lagha-Boukbiza, Ouhaid, Voirin, Jimmy, Santin, Marie des Neiges, Hainque, Elodie, Grabli, David, Comte, Alexandre, Drapier, Sophie, Durif, Franck, Marques, Ana, Eusebio, Alexandre, Azulay, Jean-Philippe, Giordana, Caroline, and Houeto, Jean-Luc

Subjects
APATHY, SUBTHALAMIC nucleus, PARKINSON'S disease, DEEP brain stimulation, EXECUTIVE function, EPISODIC memory, MOTIVATION (Psychology)
Abstract

Postoperative apathy is a frequent symptom in Parkinson's disease patients who have undergone bilateral deep brain stimulation of the subthalamic nucleus. Two main hypotheses for postoperative apathy have been suggested: (i) dopaminergic withdrawal syndrome relative to postoperative dopaminergic drug tapering; and (ii) direct effect of chronic stimulation of the subthalamic nucleus. The primary objective of our study was to describe preoperative and 1-year postoperative apathy in Parkinson's disease patients who underwent chronic bilateral deep brain stimulation of the subthalamic nucleus. We also aimed to identify factors associated with 1-year postoperative apathy considering: (i) preoperative clinical phenotype; (ii) dopaminergic drug management; and (iii) volume of tissue activated within the subthalamic nucleus and the surrounding structures. We investigated a prospective clinical cohort of 367 patients before and 1 year after chronic bilateral deep brain stimulation of the subthalamic nucleus. We assessed apathy using the Lille Apathy Rating Scale and carried out a systematic evaluation of motor, cognitive and behavioural signs. We modelled the volume of tissue activated in 161 patients using the Lead-DBS toolbox and analysed overlaps within motor, cognitive and limbic parts of the subthalamic nucleus. Of the 367 patients, 94 (25.6%) exhibited 1-year postoperative apathy: 67 (18.2%) with ' de novo apathy' and 27 (7.4%) with 'sustained apathy'. We observed disappearance of preoperative apathy in 22 (6.0%) patients, who were classified as having 'reversed apathy'. Lastly, 251 (68.4%) patients had neither preoperative nor postoperative apathy and were classified as having 'no apathy'. We identified preoperative apathy score [odds ratio (OR) 1.16; 95% confidence interval (CI) 1.10, 1.22; P < 0.001], preoperative episodic memory free recall score (OR 0.93; 95% CI 0.88, 0.97; P = 0.003) and 1-year postoperative motor responsiveness (OR 0.98; 95% CI 0.96, 0.99; P = 0.009) as the main factors associated with postoperative apathy. We showed that neither dopaminergic dose reduction nor subthalamic stimulation were associated with postoperative apathy. Patients with 'sustained apathy' had poorer preoperative fronto-striatal cognitive status and a higher preoperative action initiation apathy subscore. In these patients, apathy score and cognitive status worsened postoperatively despite significantly lower reduction in dopamine agonists (P = 0.023), suggesting cognitive dopa-resistant apathy. Patients with 'reversed apathy' benefited from the psychostimulant effect of chronic stimulation of the limbic part of the left subthalamic nucleus (P = 0.043), suggesting motivational apathy. Our results highlight the need for careful preoperative assessment of motivational and cognitive components of apathy as well as executive functions in order to better prevent or manage postoperative apathy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Imbalanced motivated behaviors according to motor sign asymmetry in drug-naïve Parkinson’s Disease

Author

Béreau, Matthieu, primary, Castrioto, Anna, additional, Servant, Mathieu, additional, Lhommée, Eugénie, additional, Desmarets, Maxime, additional, Bichon, Amélie, additional, Pelissier, Pierre, additional, Schmitt, Emmanuelle, additional, Klinger, Hélène, additional, Longato, Nadine, additional, Phillipps, Clélie, additional, Wirth, Thomas, additional, Fraix, Valérie, additional, Benatru, Isabelle, additional, Durif, Franck, additional, Azulay, Jean-Philippe, additional, Moro, Elena, additional, Broussolle, Emmanuel, additional, Thobois, Stéphane, additional, Tranchant, Christine, additional, Krack, Paul, additional, and Anheim, Mathieu, additional

Published
2023
Full Text
View/download PDF

32. Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Author

Dam, Tien, Boxer, Adam L, Yang, Lili, Shill, Holly, Shprecher, David, Stamelou, Maria, Steiger, Malcolm, Takahashi, Yuji, Takigawa, Hiroshi, Tartaglia, Carmela, Toenges, Lars, Truong, Daniel, Tse, Winona, Tidemann-Miller, Beth, Tuite, Paul, Volc, Dieter, Wills, Anne-Marie A, Woitalla, Dirk, Xie, Tao, Yuasa, Tatsuhiko, Zauber, Sarah Elizabeth, Zesiewicz, Theresa, Kupferman, Joseph, Harper, Kristine, Kamisoglu, Kubra, Wald, Michael J, Graham, Danielle L, Gedney, Liz, O'Gorman, John, Haeberlein, Samantha Budd, Golbe, Lawrence I, Group, PASSPORT Study, Aiba, Ikuko, Antonini, Angelo, Apetauerova, Diana, Azulay, Jean-Philippe, Martinez, Ernest Balaguer, Bang, Jee, Barone, Paolo, Barrett, Matthew, Bega, Danny, Höglinger, Günter, Berg, Daniela, Corrales, Koldo Berganzo, Bordelon, Yvette, Brandt, Moritz, Brueggemann, Norbert, Castelnovo, Giovanni, Ceravolo, Roberto, Chuang, Rosalind, Chung, Sun Ju, Morris, Huw R, Church, Alistair, Corvol, Jean-Christophe, Cudia, Paola, Dale, Marian, Defebvre, Luc, Drapier, Sophie, Driver-Dunckley, Erika D, Ebersbach, Georg, Eggert, Karla M, Ellenbogen, Aaron, Litvan, Irene, Eusebio, Alexandre, Evans, Andrew H, Fedorova, Natalia, Finger, Elizabeth, Foubert-Samier, Alexandra, Ghosh, Boyd, Golbe, Lawrence, Perez, Francisco Grandas, Grossman, Murray, Hall, Deborah, Lang, Anthony E, Hamada, Kyoko, Hasegawa, Kazuko, Hoeglinger, Guenter, Honig, Lawrence, Houghton, David, Huang, Xuemei, Isaacson, Stuart, Koh, SeongBeom, Bojarski, Jaime Kulisevsky, Leigh, Peter Nigel, Lozano, Juan Jose Lopez, Moreno, Jose Luis Lopez-Sendon, Ludolph, Albert Christian, Piudo, Ma Rosario Luquin, Torres, Irene Martinez, McFarland, Nikolaus, Meissner, Wassilios, Mestre, Tiago, Rivera, Pablo Mir, Molho, Eric, Mollenhauer, Britt, Murata, Miho, Obi, Tomokazu, Magne, Fabienne Ory, O'Suilleabhain, Padraig, Pahwa, Rajesh, Pantelyat, Alexander, Grundman, Michael, Pavese, Nicola, Pokhabov, Dmitry, Prudlo, Johannes, Rodriguez-Porcel, Federico, Rowe, James, Savitt, Joseph, Schnitzler, Alfons, Schulz, Joerg B, Seppi, Klaus, and Shah, Binit

Subjects
ddc:610, General Medicine, General Biochemistry, Genetics and Molecular Biology
Published
2022

34. Trial of Prasinezumab in Early-Stage Parkinson’s Disease

Author

Pagano, Gennaro, primary, Taylor, Kirsten I., additional, Anzures-Cabrera, Judith, additional, Marchesi, Maddalena, additional, Simuni, Tanya, additional, Marek, Kenneth, additional, Postuma, Ronald B., additional, Pavese, Nicola, additional, Stocchi, Fabrizio, additional, Azulay, Jean-Philippe, additional, Mollenhauer, Brit, additional, López-Manzanares, Lydia, additional, Russell, David S., additional, Boyd, James T., additional, Nicholas, Anthony P., additional, Luquin, María R., additional, Hauser, Robert A., additional, Gasser, Thomas, additional, Poewe, Werner, additional, Ricci, Benedicte, additional, Boulay, Anne, additional, Vogt, Annamarie, additional, Boess, Frank G., additional, Dukart, Juergen, additional, D’Urso, Giulia, additional, Finch, Rebecca, additional, Zanigni, Stefano, additional, Monnet, Annabelle, additional, Pross, Nathalie, additional, Hahn, Andrea, additional, Svoboda, Hanno, additional, Britschgi, Markus, additional, Lipsmeier, Florian, additional, Volkova-Volkmar, Ekaterina, additional, Lindemann, Michael, additional, Dziadek, Sebastian, additional, Holiga, Štefan, additional, Rukina, Daria, additional, Kustermann, Thomas, additional, Kerchner, Geoffrey A., additional, Fontoura, Paulo, additional, Umbricht, Daniel, additional, Doody, Rachelle, additional, Nikolcheva, Tania, additional, and Bonni, Azad, additional

Published
2022
Full Text
View/download PDF

36. Relevance of corpus callosum splenium versus middle cerebellar peduncle hyperintensity for FXTAS diagnosis in clinical practice

Author

Renaud, Mathilde, Perriard, Julien, Coudray, Sarah, Sévin-Allouet, Mathieu, Marcel, Christophe, Meissner, Wassilios G., Chanson, Jean-Baptiste, Collongues, Nicolas, Philippi, Nathalie, Gebus, Odile, Quenardelle, Véronique, Castrioto, Anna, Krack, Paul, N’Guyen, Karine, Lefebvre, François, Echaniz-Laguna, Andoni, Azulay, Jean-Philippe, Meyer, Nicolas, Labauge, Pierre, Tranchant, Christine, and Anheim, Mathieu

Published
2015
Full Text
View/download PDF

37. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial

Author

Moreau, Caroline, Delval, Arnaud, Defebvre, Luc, Dujardin, Kathy, Duhamel, Alain, Petyt, Gregory, Vuillaume, Isabelle, Corvol, Jean-Christophe, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Guehl, Dominique, Eusebio, Alexandre, Fraix, Valérie, Saulnier, Pierre-Jean, Lagha-Boukbiza, Ouhaid, Durif, Frank, Faighel, Mirela, Giordana, Caroline, Drapier, Sophie, Maltête, David, Tranchant, Christine, Houeto, Jean-Luc, Debû, Bettina, Sablonniere, Bernard, Azulay, Jean-Philippe, Tison, François, Rascol, Olivier, Vidailhet, Marie, Destée, Alain, Bloem, Bastiaan R, Bordet, Régis, and Devos, David

Published
2012
Full Text
View/download PDF

38. Fatigue in de novo Parkinson’s Disease: Expanding the Neuropsychiatric Triad?

Author

Béreau, Matthieu, primary, Castrioto, Anna, additional, Lhommée, Eugénie, additional, Maillet, Audrey, additional, Gérazime, Aurélie, additional, Bichon, Amélie, additional, Pélissier, Pierre, additional, Schmitt, Emmanuelle, additional, Klinger, Hélène, additional, Longato, Nadine, additional, Fraix, Valérie, additional, Benatru, Isabelle, additional, Durif, Franck, additional, Azulay, Jean-Philippe, additional, Moro, Elena, additional, Broussolle, Emmanuel, additional, Tranchant, Christine, additional, Anheim, Mathieu, additional, Thobois, Stéphane, additional, and Krack, Paul, additional

Published
2022
Full Text
View/download PDF

39. The clinical and humanistic value of “good on-time” among patients with advanced Parkinson’s disease: A real-world study from 7 countries (P7-11.005)

Author

Shahed, Joohi Jimenez, primary, Merola, Aristide, additional, Malaty, Irene, additional, Azulay, Jean-Philippe, additional, Yan, Connie, additional, Kharat, Aditi, additional, Alobaidi, Ali, additional, Kandukuri, Prasanna, additional, Kukreja, Pavnit, additional, Zamudio, Jorge, additional, Gillespie, Alexander, additional, and Antonini, Angelo, additional

Published
2022
Full Text
View/download PDF

40. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies

Author

Rascol, Olivier, primary, Tönges, Lars, additional, deVries, Tina, additional, Jaros, Mark, additional, Quartel, Adrian, additional, Jacobs, David, additional, Azulay, Jean-Philippe, additional, Balaguer, Ernest, additional, Bhatia, Perminder, additional, Bodis-Wollner, Ivan, additional, Brownstone, Paul, additional, Boulloche, Nicolas, additional, Calegan, Gerald J., additional, Castelnovo, Giovanni, additional, Chou, Kelvin L., additional, Corvol, Jean-Christophe, additional, Danisi, Fabio, additional, Defebvre, Luc, additional, Desojo, Lydia Vela, additional, Durif, Franck, additional, Ehret, Reinhard, additional, Evans, Bradley K., additional, Forchetti, Concetta, additional, Friedman, Joseph H., additional, Fogel, Wolfgang, additional, Garniga, Matilde Calopa, additional, Gil, Ramon A., additional, Ginsberg, Paul L., additional, Glasberg, Mark R., additional, Griffith, Alida, additional, Groves, Jeffrey W., additional, Gudesblatt, Mark, additional, Hermanowicz, Neal, additional, Herrera, Maria A., additional, Houeto, Jean-Luc, additional, Hutchman, Robert M., additional, Isaacson, Stuart H., additional, Jagadeesan, Singar, additional, Jog, Mandar, additional, Keegan, Andrew, additional, Klostermann, Fabian, additional, Krystkowiak, Pierre, additional, Kulisevsky Bojarsky, Jaime, additional, Kumar, Rajeev, additional, Lacey, Dennis, additional, Lasker, Bruce, additional, LaVaccare, John, additional, Lavallee, Michelle M., additional, Piudo, Maria Rosario Luquin, additional, Mahler, Andreas, additional, Domenech, Maria José Martí, additional, Martinez Castrillo, Juan Carlos, additional, Mate, Laszlo J., additional, Mendis, Tilak, additional, Metman, Leonard Verhagen, additional, Muhlack, Siegfried Martin, additional, Müller, Thomas, additional, Park, Ariane, additional, Patton, James, additional, Peckham, Elizabeth, additional, Grandas Pérez, Francisco, additional, Rabin, Marcie, additional, Rascol, Olivier, additional, Reifschneider, Gerd, additional, Remy, Philippe, additional, Rivera, Pablo Mir, additional, Schwarz, Johannes, additional, Roullet-Solignac, Isabelle, additional, Salazar, Gabriel, additional, Sergay, Stephen M., additional, Sherman, Scott, additional, Shubin, Richard, additional, Spikol, Lorraine, additional, Steigerwald, Frank, additional, Truong, Daniel D., additional, Ugarte, Antonio, additional, Vivancos Matellano, Francisco, additional, Witte, Arnold, additional, Zesiewicz, Theresa, additional, and Zauber, Sarah Elizabeth, additional

Published
2022
Full Text
View/download PDF

41. Trial of Prasinezumab in Early-Stage Parkinson's Disease

Author

Pagano, Gennaro, Taylor, Kirsten I, Mollenhauer, Brit, López-Manzanares, Lydia, Russell, David S, Boyd, James T, Nicholas, Anthony P, Luquin, María R, Hauser, Robert A, Gasser, Thomas, Poewe, Werner, Ricci, Benedicte, Anzures-Cabrera, Judith, Boulay, Anne, Vogt, Annamarie, Boess, Frank G, Dukart, Juergen, D'Urso, Giulia, Finch, Rebecca, Zanigni, Stefano, Monnet, Annabelle, Pross, Nathalie, Hahn, Andrea, Marchesi, Maddalena, Svoboda, Hanno, Britschgi, Markus, Lipsmeier, Florian, Volkova-Volkmar, Ekaterina, Lindemann, Michael, Dziadek, Sebastian, Holiga, Štefan, Rukina, Daria, Kustermann, Thomas, Kerchner, Geoffrey A, Simuni, Tanya, Fontoura, Paulo, Umbricht, Daniel, Doody, Rachelle, Nikolcheva, Tania, Bonni, Azad, Investigators, PASADENA, Group, Prasinezumab Study, Marek, Kenneth, Postuma, Ronald B, Pavese, Nicola, Stocchi, Fabrizio, and Azulay, Jean-Philippe

Subjects
Dopamine Plasma Membrane Transport Proteins, Parkinson Disease, General Medicine, therapeutic use [Antibodies, Monoclonal, Humanized], Antibodies, Monoclonal, Humanized, drug therapy [Parkinson Disease], Antiparkinson Agents, Treatment Outcome, Double-Blind Method, therapeutic use [Dopamine Plasma Membrane Transport Proteins], alpha-Synuclein, Humans, ddc:610, antagonists & inhibitors [alpha-Synuclein], therapeutic use [Antiparkinson Agents]
Abstract

Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease.In this phase 2 trial, we randomly assigned participants with early-stage Parkinson's disease in a 1:1:1 ratio to receive intravenous placebo or prasinezumab at a dose of 1500 mg or 4500 mg every 4 weeks for 52 weeks. The primary end point was the change from baseline to week 52 in the sum of scores on parts I, II, and III of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 236, with higher scores indicating greater impairment). Secondary end points included the dopamine transporter levels in the putamen of the hemisphere ipsilateral to the clinically more affected side of the body, as measured by 123I-ioflupane single-photon-emission computed tomography (SPECT).A total of 316 participants were enrolled; 105 were assigned to receive placebo, 105 to receive 1500 mg of prasinezumab, and 106 to receive 4500 mg of prasinezumab. The baseline mean MDS-UPDRS scores were 32.0 in the placebo group, 31.5 in the 1500-mg group, and 30.8 in the 4500-mg group, and mean (±SE) changes from baseline to 52 weeks were 9.4±1.2 in the placebo group, 7.4±1.2 in the 1500-mg group (difference vs. placebo, -2.0; 80% confidence interval [CI], -4.2 to 0.2; P = 0.24), and 8.8±1.2 in the 4500-mg group (difference vs. placebo, -0.6; 80% CI, -2.8 to 1.6; P = 0.72). There was no substantial difference between the active-treatment groups and the placebo group in dopamine transporter levels on SPECT. The results for most clinical secondary end points were similar in the active-treatment groups and the placebo group. Serious adverse events occurred in 6.7% of the participants in the 1500-mg group and in 7.5% of those in the 4500-mg group; infusion reactions occurred in 19.0% and 34.0%, respectively.Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. (Funded by F. Hoffmann-La Roche and Prothena Biosciences; PASADENA ClinicalTrials.gov number, NCT03100149.).

Published
2022

45. Delayed-Onset Friedreichʼs Ataxia Revisited

Author

Lecocq, Claire, Charles, Perrine, Azulay, Jean-Philippe, Meissner, Wassilios, Rai, Myriam, NʼGuyen, Karine, Péréon, Yann, Fabre, Nelly, Robin, Elsa, Courtois, Sylvie, Guyant-Maréchal, Lucie, Zagnoli, Fabien, Rudolf, Gabrielle, Renaud, Mathilde, Sévin-Allouet, Mathieu, Lesne, Fabien, Alaerts, Nick, Goizet, Cyril, Calvas, Patrick, Eusebio, Alexandre, Guissart, Claire, Derkinderen, Pascal, Tison, Francois, Brice, Alexis, Koenig, Michel, Pandolfo, Massimo, Tranchant, Christine, Dürr, Alexandra, and Anheim, Mathieu

Published
2016
Full Text
View/download PDF

47. Liste des auteurs

Author

Defebvre, Luc, primary, Vérin, Marc, additional, Anheim, Mathieu, additional, Azulay, Jean-Philippe, additional, Bleton, Jean-Pierre, additional, Brefel-Courbon, Christine, additional, Broussolle, Emmanuel, additional, Chrysostome, Virginie, additional, Corvol, Jean-Christophe, additional, Damier, Philippe, additional, Defebvre, Luc, additional, Derkinderen, Pascal, additional, Dujardin, Kathy, additional, Dürr, Alexandra, additional, Duyckaerts, Charles, additional, Fénelon, Gilles, additional, Fraix, Valérie, additional, Joyon, Natacha, additional, Krystkowiak, Pierre, additional, Lohmann, Ebba, additional, Maltête, David, additional, Moreau, Caroline, additional, Ory-Magne, Fabienne, additional, Robert, Gabriel, additional, Thobois, Stéphane, additional, Tison, François, additional, Viallet, François, additional, Vidailhet, Marie, additional, and Witjas, Tatiana, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results